Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
| Author | |
|---|---|
| Abstract | :
Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit. |
| Year of Publication | :
2019
|
| Journal | :
The New England journal of medicine
|
| Volume | :
380
|
| Issue | :
8
|
| Number of Pages | :
752-762
|
| Date Published | :
2019
|
| ISSN Number | :
0028-4793
|
| URL | :
http://www.nejm.org/doi/full/10.1056/NEJMoa1809798?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI | :
10.1056/NEJMoa1809798
|
| Short Title | :
N Engl J Med
|
| Download citation |